Bayer Radiology Medical Affairs Department is interested in receiving and reviewing Grant Applications to support appropriate programs as described below.

Radiology

Intended Audience: Radiologists, MRI Technologists, Referring Physicians, MRI Nurses, Pharmacists.

Bayer Radiology Rationale for Educational Support:

Areas of interest based on referenced literature:

• Gadavist-enhanced MRI applications and protocols
• Pediatric applications and protocols for Gadavist-enhanced MRI
• Physiologic understanding of gadolinium and its properties
• Radiation and contrast dose monitoring and optimization
• Optimum protocols for power injector use in CT and MRI
• Injector use in PET
• Patient education and understanding such as breast MRI

Accredited Proposal Requirements:

The proposal must be compliant with standards and guidelines for commercial support (e.g., ACCME).

The proposal should include:

• Needs Assessment
• Educational Design and Rationale for Selection
• Learning Objectives
• Proposed Faculty
• Participant Recruitment Plan
• Outcomes Strategy/plan
• Definition of Successful Program
• Detailed Budget (must use the template available on the website)

Provider Justification:

1. Copy of most recent accreditation letter and status
2. Samples of other programs in similar therapeutic areas

Process

Applications/proposals which are submitted and determined to be complete are reviewed monthly.

Acceptance of a Bayer educational grant indicates that you will:

• Reconcile grant funding within 60 days of completion of the educational program
• Permit a Bayer Medical Affairs representative to audit live programs of at least $5000 (Bayer Compliance staff may also audit live programs and/or review the use of the grant)
• Share activity data and outcomes metrics within 30 days of their availability

Literature/Data Referenced

1. Abujudeh HH, Dosaraju, VK, Kaewlai R, Acute adverse reactions to gadopentetate dimeglumine and gadobenate dimeglumine: experience with 32,659 injections, AJR AM J Roentgenol. 2010 Feb; 194(2); 430-434.
2. Altun E, Martin DR, Wertman R, et al. Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy-report from two US universities. Radiology. 2009 Dec; 253(3):689-696. Epub 2009 Sept 29.
3. Bellin MF, Van Der Molen AJ. Extracellular gadolinium-based contrast media: an overview. Eur J Radiol. 2008 May; 66(2):160-167. Epub 2008 Mar20.Review.
4. Forsting M, Palkowitsch P. Prevalence of acute adverse reactions to gadobutrol-a highly concentrated macrocyclic gadolinium chelate: review of 14,299 patients from observational trials. Eur J Radiol. 2010 Jun; 74(3):e186-192. Epub 2009 Jul2.
5. Ge Y, Multiple sclerosis: the role of MR imaging, AJNR Am J Neuroradiol, 2006; 27: 1165-76.
6. Kurtkoti, J., et al. Gadolinium and Nephrogenic Systemic Fibrosis: Association or Causation, Nephrology June 2008;13: 235-41.
7. Lin SP, Brown JJ. MR contrast agents. Physical and pharmacologic basics. J Magn Reson Imaging. 2007; 25:884-899 Abstract.
8. Morcos SK. Extracellular gadolinium contrast agents: difference in stability. Eur J Radiol. 2008 May;66(2): 175-179. Epub 2008 Mar14.
9. Provenzale JM, Mukundan S, Barboriak DP. Diffusion-weighted and perfusion MR imaging for brain tumor characterization and assessment of treatment response. Radiology. 2006 Jun;239(3):632-49. (2006) Abstract.
10. ACR Practice Guideline for Performing and Interpreting Magnetic Resonance Imaging (MRI)., Available at the American College of Radiology web site:
    http://www.acr.org/~/media/ACR/Documents/PDF/QualitySafety/Resources/Contrast Manual/FullManual.pdf.